Don't miss this #VJHemOnc interview 👉 tinyurl.com/3u7dkrhn
@ash-hematology.bsky.social #MultipleMyeloma #MMsm
Don't miss this #VJHemOnc interview 👉 tinyurl.com/3u7dkrhn
@ash-hematology.bsky.social #MultipleMyeloma #MMsm
We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed
#Hemesky
We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed
#Hemesky
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Free-to-read link: rdcu.be/d09QN
Free-to-read link: rdcu.be/d09QN
www.nature.com/articles/d41...
www.nature.com/articles/d41...
www.nature.com/immersive/d4...
www.nature.com/immersive/d4...
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
An important footnote for all the CAR-T vs bsAb efficacy debates: when stratified by MRD status, CAR-T and bsAbs do identically.
Getting to MRD neg is what matters!
onlinelibrary.wiley.com/doi/10.1002/...
An important footnote for all the CAR-T vs bsAb efficacy debates: when stratified by MRD status, CAR-T and bsAbs do identically.
Getting to MRD neg is what matters!
onlinelibrary.wiley.com/doi/10.1002/...